World Journal of Pharmaceutical Science and Research

www.wjpsronline.com

Review Article

ISSN: 2583-6579
SJIF Impact Factor: 6.916
Year - 2026
Volume: 5; Issue: 7
Page: 596-619

COMPUTER -AIDED DRUG DESIGN (CADD): VIRTUAL SCREENING OF DRUG CANDIDATES IN MODERN DRUG DISCOVERY-A COMPREHENSIVE REVIEW

Reshma Banu S.*[1], Javairiya Afra J.[2], Abhinaya K. R.[3], Ajay kumar S. N.[4], Dr. E. Gopinath[5]

[1]Assistant Professor, Department of Pharmaceutics, Shantha College of Pharmacy, Peresandra, Chikkaballapura, Karnataka -562104.

[2,3]Student, Shantha College of Pharmacy, Peresandra, Chikkaballapura, Karnataka-562104.

[4]Assistant Professor, Department of Pharmaceutics, Shantha College of Pharmacy, Peresandra, Chikkaballapura, Karnataka-562104.

[5]Principal, Department of Pharmaceutics, Shantha College of Pharmacy, Peresandra, Chikkaballapura, Karnataka-562104.

Article Received: 27 May 2026 | | ***Article Revised: 17 June 2026*** | | ***Article Accepted: 08 July 2026***

***Corresponding Author: Reshma Banu S.**
Assistant Professor, Department of Pharmaceutics, Shantha College of Pharmacy, Peresandra, Chikkaballapura, Karnataka -562104.
DOI: https://doi.org/10.5281/zenodo.21371577

How to cite this Article: Reshma Banu S., Javairiya Afra J., Abhinaya K. R., Ajay kumar S. N., Dr. E. Gopinath (2026) COMPUTER -AIDED DRUG DESIGN (CADD): VIRTUAL SCREENING OF DRUG CANDIDATES IN MODERN DRUG DISCOVERY-A COMPREHENSIVE REVIEW. World Journal of Pharmaceutical Science and Research, 5(7), 596-619.

ABSTRACT

Computer-Aided Drug Discovery (CADD) is a newly introduced technology, which is a highly sophisticated computational technique that enhances the efficacy of the process of drug discovery.[6,14,15] The traditional drug discovery process involves high cost, time consumption, and a high probability of failure during the various phases of development. CADD is a rational process that involves the use of computational chemistry, molecular modeling, bioinformatics, and artificial intelligence to develop therapeutic compounds.[1,3,4] Various CADD methods, the virtual screening method has proved to be a significant tool for the speedy identification of potential drug candidates from massive databases of chemicals. Virtual screening facilitates the computational testing of thousands of compounds according to their molecular properties, target interactions, binding affinities, and drug-like properties prior to experimentally verifying them. Methods like molecular docking, molecular dynamic simulation, QSAR study, pharmacophore modeling, and ADMET predictions can be helpful for the selection and improvement of lead molecules.[1,3,4] The incorporation of artificial intelligence and machine learning techniques has further improved the capability of CADD for predicting drug-target interactions, toxicity, and molecular design.[6,14,16] The virtual screening approach based on CADD is widely used in the discovery of therapeutic agents for cancer, infectious diseases, neurodegenerative diseases, and others.[1,3,4] This review focuses on the concepts, evolution, techniques, applications, merits, demerits, and future prospects of CADD with special attention to the virtual screening for modern drug discovery.[6,14,15]

KEYWORDS: Computer-Aided Drug Design, Virtual Screening, Molecular Docking, QSAR, Drug Discovery, Artificial Intelligence, Lead Optimization.

1. INTRODUCTION

Drug discovery is a complex, multidisciplinary, and time-consuming process involving target identification, lead discovery, lead optimization, preclinical studies, and clinical evaluation. Traditional drug discovery approaches mainly depend on experimental screening methods, which require extensive resources, high financial investment, and longer development periods.[5,19] Additionally, many potential drug candidates fail during development due to poor efficacy, toxicity, or unsuitable pharmacokinetic properties.[1,2, 3]

The advancement of computational technologies has introduced Computer-Aided Drug Design (CADD) as a powerful and innovative approach to improve the efficiency of drug discovery. CADD utilizes computer-based methods to analyze molecular structures, predict biological activity, evaluate drug target interactions, and identify potential drug candidates before laboratory testing.[1,2,19]

A major application of CADD is virtual screening, which allows researchers to rapidly evaluate large libraries of chemical compounds and identify molecules with potential therapeutic activity. Virtual screening reduces the number of compounds requiring experimental testing and helps in selecting promising lead molecules based on predicted binding affinity, structural properties, and pharmacological characteristics.[3,5,19]

Modern CADD approaches include structure-based drug design (SBDD), ligand-based drug design (LBDD), molecular docking, molecular dynamics simulation, QSAR modelling, pharmacophore modelling, and AI-based drug design. These techniques have significantly contributed to the discovery and optimization of novel therapeutic agents.[5,19]

The integration of CADD with artificial intelligence, machine learning, and big data analysis has further transformed modern drug discovery by enabling faster, more accurate, and cost-effective development of safer medicines.[1,2,3]

Table 1: Comparison of commonly used computer-aided drug design (CADD) software.

Software	Application	Advantages
AutoDock Vina	Molecular Docking	Free, rapid, precise
Schrodinger Glide	Docking	Precision and widely used
GOLD	Flexible Docking	Flexible protein structure
MOE	Drug Design	Docking, QSAR and pharmacophores in one software
Discovery Studio	Visualization	Simple interaction study

1. History And Development of Computer -Aided Drug Design [CADD]

With advancements in computational power, molecular modelling became an important component of CADD. Molecular modelling involves the creation and analysis of three-dimensional representations of molecules to study their structure, stability, and interactions.

Techniques such as molecular mechanics and molecular dynamics simulation allowed researchers to study protein structures, ligand interactions, and molecular flexibility. The availability of protein databases and structural information further enhanced the application of molecular modelling in drug discovery.[1,2,5,11]

Significant increase of computational power, structure biology studies, and development of chemical databases during last two decades have led to the expansion of CADD capabilities. The creation of highly productive platforms for virtual screening, improvements of molecular docking and simulation algorithms have allowed analysing huge numbers of chemicals.[20,21] Moreover, recent advances in artificial intelligence, deep learning, and the use of knowledge graphs

have brought new approaches to the CADD such as target prediction, lead identification, and molecular optimization. Such technological innovations have proved the fact that computer-aided drug design has become an important part of modern pharmaceutical research and drug discovery process.[22,23]

1.1 Early Computational approaches

The foundation of CADD was established during the 1960s and 1970s with the introduction of computer-based methods for studying molecular structures and chemical properties. Early computational approaches focused on molecular geometry calculations, energy minimization, and analysis of molecular characteristics.

These methods allowed researchers to understand the relationship between molecular structure and biological activity, providing a scientific basis for rational drug design. The development of computational algorithms enabled the prediction of molecular behaviour and improved the understanding of drug-like properties.[1,2,5,11]

1.2 Development of Molecular Modelling

With advancements in computational power, molecular modelling became an important component of CADD.

Molecular modelling involves the creation and analysis of three-dimensional representations of molecules to study their structure, stability, and interactions.

Techniques such as molecular mechanics and molecular dynamics simulation allowed researchers to study protein structures, ligand interactions, and molecular flexibility. The availability of protein databases and structural information further enhanced the application of molecular modelling in drug discovery.[2,5,11]

1.3 Growth of Molecular Docking, QSAR, and Virtual Screening

The advancement of CADD led to the development of several computational techniques that improved the efficiency of drug discovery.

Molecular Docking

Molecular docking emerged as a powerful technique for predicting the interaction between a drug molecule and its biological target. It evaluates binding affinity, molecular orientation, and interaction patterns, helping identify potential therapeutic compounds.

QSAR (Quantitative Structure–Activity Relationship):

QSAR methods established mathematical relationships between chemical structures and biological activities. These models helped predict drug potency and optimize molecular structures.

Virtual Screening

Virtual Screening is one of the major developments in CADD, where large collections of chemical compounds can be screened virtually. This technology aids in finding drug candidates through prediction of their binding properties and similarity to known drugs before doing any laboratory tests.

Virtual screening has saved a lot of time and money involved in the early stages of drug development process.

1.4 Role of Artificial Intelligence and Machine Learning in Modern CADD

In recent Years, Artificial Intelligence (AI) AND MACHINE learning (ML) have revolutionized CADD by improving the accuracy and speed of computational predictions. AI-based approaches analyze large chemical and biological datasets to identify patterns and predict drug-related properties.

They have proved to be revolutionary in modern computer-aided drug design (CADD). AI-based algorithms efficiently analyze large-scale chemical, biological, genomic and pharmacological data to find the relationship between molecular structure and biological activity.[26,27,30] The deep learning methods enhance the virtual screening by predicting binding affinities, molecular properties, toxicity and ADMET profiles of molecules prior to experimental confirmation.[36,43]

Molecular generation, protein structure prediction and automated lead optimization using AI have speeded up the process of drug discovery with reduced research costs and time consumption. Moreover, the combination of AI with molecular docking, molecular dynamic simulation, QSAR, pharmacophore modeling and omics approaches has improved the identification of novel drugs and personalized medicines.[47,46] In summary, AI has made the process of CADD intelligent and efficient for modern drug discovery.[32,33]

AI and ML techniques are used for:

- Prediction of drug–target interactions
- Binding affinity estimation
- Toxicity prediction
- ADMET property analysis
- Generation of novel drug-like molecules

Deep learning approaches have further enhanced virtual screening by improving compound prioritization and accelerating the identification of promising drug candidates.

The integration of AI, machine learning, and computational modelling has transformed CADD into a highly efficient platform for modern drug discovery and personalized medicine.[1,2,5,11]

2. Drug Discovery Process and Challenges

Drug discovery is a complex and systematic process that involves the identification, development, and evaluation of new therapeutic molecules. It includes multiple stages starting from the identification of a disease-related target to the final clinical approval of a drug candidate. Although recent advances in computational technologies such as CADD have improved the efficiency of drug discovery, challenges such as high cost, long development time, and high failure rates still remain.[5,19,1]

In spite of the numerous advances in the field of technology, the discovery of drugs is associated with high risk and high costs, as well as long processes. The search for appropriate targets, the choice of promising lead compounds, and their optimization are among the most challenging tasks at the moment.[20,21,23] With the growing number of compounds in the libraries, experimental screening becomes rather difficult and impossible. Therefore, there is a need to utilize computational virtual screening. Moreover, artificial intelligence, parallel computing platforms, and large biomedical databases increase the speed and accuracy of calculations and reduce computational time.[24,25]

2.1 TARGET IDENTIFICATION

Target identification is the initial step of the drug discovery process, where researchers identify specific biological molecules involved in disease development and progression. A drug target may include proteins, enzymes, receptors, or genetic components that play a critical role in disease mechanisms.

The selected target should have a clear biological function and should provide an opportunity for therapeutic intervention. Modern approaches such as genomics, proteomics, bioinformatics, and computational analysis assist in identifying potential drug targets.

Challenges:

- Understanding complex disease pathways
- Selecting highly specific and clinically relevant targets
- Avoiding unwanted effects due to non-specific target interactions.[5,19,1]

It is one of the first and most important steps in the process of drug discovery. Modern approaches in computer science include bioinformatics, genomics, proteomics, structural biology, and artificial intelligence for the identification of disease-related proteins, enzymes, receptors, and pathways.[26,27,32] The computational models that use artificial intelligence are designed to screen large amounts of biological data to select druggable targets, structure prediction, and identify binding sites in proteins, as well as biomarkers for disease progression.[43,48] The combination of AlphaFold, network pharmacology, and systems biology methods has helped to improve the process of target selection and decrease the amount of time spent on experiments.[34,35]

2.2 LEAD DISCOVERY

Lead discovery involves the identification of promising chemical compounds that show potential activity against a selected biological target. These compounds, known as lead molecules, serve as the starting point for further drug development.

Lead compounds may be identified from natural products, synthetic chemical libraries, high-throughput screening, and computational approaches such as virtual screening.

CADD-based virtual screening helps evaluate thousands of compounds and selects potential candidates based on molecular properties, binding affinity, and predicted biological activity.

Challenges in Lead Discovery

- Screening large numbers of chemical compounds
- Identifying molecules with high potency and selectivity
- Reducing the risk of toxicity and poor drug-like properties.[5,19,1]

The discovery of leads is one of the basic steps in the drug discovery process in which biologically active substances are discovered in relation to a validated therapeutic target.[33,36,38] In modern CADD, virtual screening, molecular docking, pharmacophore modeling, QSAR, molecular fingerprinting and AI predictive models are used to quickly assess millions of compounds from large chemical databases.[27,30,31] The artificial intelligence technique plays a vital role in hit generation as it makes predictions about biological activity, binding affinity, interactions and drug-likeness

before the experimental work starts. The deep learning technique is also used in de novo drug design as it creates new compounds with desirable characteristics.[41]

2.3 Lead Optimization

Lead optimization is the process of improving the chemical and biological properties of lead compounds to develop effective and safe drug candidates.

During this stage, structural modifications are performed to improve:

- Biological activity
- Target selectivity
- Stability

Absorption, Distribution, Metabolism, and Excretion (ADME) properties.

CADD techniques such as QSAR modelling, molecular docking, and ADMET prediction support lead optimization by predicting the effects of structural changes.

It is associated with the structural changes in lead molecules that help improve their potency, selectivity, pharmacokinetics, and therapeutic efficiency [45,46]. Modern CADD approaches make use of molecular docking, molecular dynamics simulation, QSAR modeling, pharmacophore modeling, quantum mechanics computations, and ADMET predictions for optimization of molecular structures [26,27,32]. Machine learning and artificial intelligence contribute even more in this respect by predicting the effect of these changes on the biological activity, toxicity, metabolism, and drug-target interactions. As a result of all these activities, novel analogs are designed with better efficacy and reduced side effects.[37,42,44]

Challenges in Lead Optimization

- Maintaining therapeutic activity while reducing toxicity
- Improving pharmacokinetic properties
- Achieving a balance between potency and safety.[5,19,1]



Figure 1: Conventional drug discovery Workflow From chemical Library screening to drug approval.

2.4 Preclinical and Clinical Evaluation

After successful lead optimization, drug candidates undergo preclinical and clinical evaluation to determine their safety and effectiveness.

Preclinical Evaluation

Preclinical studies involve laboratory and animal-based investigations to evaluate:

- Pharmacological activity
- Toxicity profile
- Pharmacokinetic and pharmacodynamic properties

These studies provide essential information before human testing.

Clinical Evaluation

Clinical trials are performed in humans to assess safety, efficacy, and appropriate dosage.

Clinical trial phases include:

- Phase I: Evaluates safety, tolerability, and dosage range.
- Phase II: Evaluates therapeutic effectiveness and monitors side effects.
- Phase III: Confirms efficacy and safety in a larger population.

Challenges in Preclinical and Clinical Evaluation:

- High cost and long duration
- Failure of drug candidates during trials
- Regulatory approval requirements.[5,19,1]

After lead optimization, the use of computational methods to aid in drug discovery does not cease but carries on into the stages of preclinical and clinical evaluation. Computational ADMET models make predictions about absorption, distribution, metabolism, excretion, toxicity, and any possible interactions of the drug with other drugs before animal testing begins.[36,47] The use of machine learning algorithms helps predict toxicity, identify biomarkers, optimize clinical trials, segregate patient population, and predict treatment outcomes.[47,43] The use of real-world biomedical datasets together with AI improves clinical decision making and supports precision medicine.[26,27,30]

3. Role of Computer-Aided Drug Design (CADD) in Drug Discovery Process

Computer-Aided Drug Design (CADD) plays an important role in modern drug discovery by providing computational methods for the identification, analysis, and optimization of potential therapeutic molecules. CADD approaches reduce the time, cost, and experimental workload associated with conventional drug discovery by predicting molecular behaviour and drug-related properties before laboratory testing.[6,7,19]

The major roles of CADD in the drug discovery process include target prediction, virtual screening, molecular docking, ADMET prediction, and lead optimization.[1,3,7,19]

3.1 TARGET PREDICTION

Target prediction is an important application of CADD that helps identify suitable biological targets involved in disease progression. Computational approaches analyze biological data, molecular pathways, and structural information to predict potential proteins, enzymes, or receptors that can be targeted for therapeutic intervention.

CADD-based target prediction supports the understanding of disease mechanisms and helps researchers select appropriate targets for drug development.[6,7,13]

Significance

- Identification of disease-associated molecular targets
- Understanding biological mechanisms
- Supporting rational drug design strategies.[1,3,13]

3.2 VIRTUAL SCREENING

Virtual screening is one of the most important applications of CADD used for the rapid identification of potential drug candidates from large chemical libraries. It involves computational evaluation of thousands to millions of compounds based on their structural properties, molecular interactions, and predicted biological activity.[6,7]

Virtual screening methods are mainly classified into:

- Structure-based virtual screening
- Ligand-based virtual screening

It helps prioritize promising compounds for further experimental evaluation and reduces the number of molecules requiring laboratory testing.

Significance

- Accelerates lead identification
- Reduces time and cost of drug discovery
- Selects compounds with better drug-like properties.[1,3,6]

3.3 MOLECULAR DOCKING

Molecular docking is a computational tool that predicts the interaction of a ligand molecule with a target molecule like a protein or an enzyme.[1,3,6,7]

Molecular docking studies assess

- Binding affinity
- Binding energy
- Hydrogen bond interactions
- Hydrophobic interactions

It helps in understanding the binding mechanism and identifying potentially active molecules.

Importance

- Determines interactions between a drug and its target
- Provides support for structure-based drug design
- Helps in lead selection and optimization [1,3,6].



Figure 2: Protein–ligand interaction obtained through molecular docking.

3.4 ADMET Prediction

ADMET prediction refers to the computational evaluation of Absorption, Distribution, Metabolism, Excretion, and Toxicity properties of drug candidates.

CADD tools predict pharmacokinetic behaviour and possible toxicity risks during the early stages of drug discovery.[1,3,6]

Significance

- Improves drug safety assessment
- Reduces late-stage drug failure
- Helps select compounds with suitable pharmacological properties.[1,3,6]

3.5 Lead Optimization

Lead optimization involves improving the properties of identified lead molecules to develop effective and safe drug candidates.[1,3,6]

CADD techniques such as QSAR analysis, molecular modelling, and computational simulations help modify molecular structures to improve:

- Potency
- Selectivity
- Stability
- Pharmacokinetic properties

Significance

- Enhances therapeutic activity
- Reduces toxicity risk
- Improves overall drug performance.[6,7,13]



Figure 3: Role of CADD in Different Stages of Drug Discovery.

4. Major Approaches of Computer-Aided Drug Design (CADD)

Computer-Aided Drug Design (CADD) approaches are mainly divided into two major categories: Structure-Based Drug Design (SBDD) and Ligand-Based Drug Design (LBDD). These approaches help researchers understand molecular interactions, predict biological activity, and design or optimize potential drug candidates. The selection of a particular approach depends on the availability of target structure and information about known active molecules.

STRUCTURE-BASED DRUG DESIGN (SBDD)

Structure-Based Drug Design is a computational approach that uses the three-dimensional structure of a biological target, such as proteins, enzymes, or receptors, for drug discovery and optimization.

SBDD is based on the understanding that the interaction between a drug molecule and its target determines the biological response. The availability of protein structures obtained from techniques such as X-ray crystallography, Nuclear Magnetic Resonance (NMR), and cryo-electron microscopy has improved the application of SBDD.[6,7,8]

Major techniques involved in SBDD include:

- Molecular docking
- Molecular dynamics simulation
- Virtual screening
- Binding energy calculation

SBDD helps predict how a ligand binds to the active site of a target molecule by analysing interactions such as hydrogen bonding, hydrophobic interactions, and electrostatic forces.[2,3,6]

Applications of SBDD

- Identification of novel drug candidates
- Designing selective inhibitors
- Understanding drug–target interactions
- Lead optimization

Advantages of SBDD

- Provides detailed information about molecular interactions
- Supports rational drug design
- Reduces experimental screening requirements.[2,3,6]

Limitations of SBDD

- Requires accurate three-dimensional target structures
- Protein flexibility may affect prediction accuracy.[6,7,8]

4.2 Ligand-Based Drug Design (LBDD)

Ligand-Based Drug Design is a computational approach used when the three-dimensional structure of the biological target is unavailable, but information about known active compounds is available.[11,12,13]

LBDD focuses on analysing the chemical and structural features of active molecules to identify important characteristics responsible for biological activity. These features are used to design new molecules with improved therapeutic properties.[11,12,13]

Major techniques involved in LBDD include:

- Quantitative Structure–Activity Relationship (QSAR)
- Pharmacophore modelling
- Similarity searching
- Molecular descriptor analysis.[11,12,13]

LBDD approaches help predict the activity of new compounds by comparing them with known active molecules.

Applications of LBDD

- Prediction of biological activity
- Identification of new lead molecules
- Lead optimization
- Drug candidate selection.[11,12,13]

Advantages of LBDD

- Does not require target structure information
- Useful for optimization of known active compounds

- Helps in designing improved drug molecules.[11,12,13]

Limitations of LBDD

- Depends on availability of known active compounds
- Prediction accuracy depends on quality of available data.[11,12,13]

Table 2: Comparison between SBDD and LBDD.

Feature	Structure-Based Drug Design (SBDD)	Ligand-Based Drug Design (LBDD)
Requirement	3D structure of biological target	Information about known ligand
Main emphasis	Drug–target interaction	Structure–activity relationship
Primary methods used	Docking, molecular dynamics, virtual screening	QSAR, pharmacophore modeling
uses	Identification of new drugs	Ligand optimization and lead identification
Restriction	Knowledge of target's structure is necessary	Information of ligands is necessary

5. Major Techniques of Computer-Aided Drug Design (CADD)



Figure 4: Major computational techniques employed in computer-aided drug design(CADD).

Computer-Aided Drug Design (CADD) involves various computational techniques that support the identification, evaluation, and optimization of potential drug candidates. These techniques help predict molecular interactions, biological activity, pharmacokinetic properties, and safety profiles before experimental testing. The major CADD techniques include virtual screening, molecular docking, molecular dynamics simulation, QSAR, pharmacophore modelling, and artificial intelligence/machine learning-based drug design.

5.1 Virtual Screening

Virtual screening is one of the most important techniques in CADD used for the rapid identification of potential drug candidates from large chemical databases. It involves computational evaluation of thousands or millions of compounds to identify molecules with suitable biological activity and drug-like properties [3,7,18].

Virtual screening is mainly classified into:

1. Structure-Based Virtual Screening (SBVS)

This approach uses the three-dimensional structure of a biological target to identify compounds that can bind effectively with the active site.

2. Ligand-Based Virtual Screening (LBVS)

This approach uses information from known active molecules to identify structurally similar compounds with potential activity.

Applications

- Hit identification
- Lead discovery
- Drug repurposing
- Screening of large chemical libraries.[3,7,18]

Importance

Virtual screening reduces experimental workload, time, and cost by prioritizing promising drug candidates before laboratory evaluation.

5.2 Molecular Docking

Molecular docking is a computational method used to predict the interaction between a ligand and a biological target such as a protein, enzyme, or receptor.[6,7,8,9]

Docking studies determine the preferred orientation of a molecule within the active site and evaluate the strength of interaction.[6,7,8,9]

Important parameters include

- Binding affinity
- Binding energy
- Hydrogen bonding
- Hydrophobic interactions.[6,7,8,9]

Applications

- Prediction of drug–target interactions
- Identification of active compounds
- Structure-based drug design

Importance

Molecular docking helps researchers understand molecular interactions and select compounds with better therapeutic potential.[6,7,8,9]

Table 3: Ai methods and their usage in CADD.

AI method	Usage
Machine Learning	Prediction of drug targets
Deep Learning	Creation of new molecules
AlphaFold	Protein structure prediction
Generative AI	New molecule design
Graph Neural Networks (GNNs)	Predict molecular properties

5.3 Molecular Dynamics (MD) Simulation

Molecular Dynamics simulation is a computational technique used to study the movement, flexibility, and stability of molecules over time.[10,17]

It evaluates the behaviour of protein–ligand complexes under simulated physiological conditions.[10,17]

Important parameters include

- Root Mean Square Deviation (RMSD)
- Root Mean Square Fluctuation (RMSF)
- Radius of gyration
- Hydrogen bond analysis.[10,17]

Applications

- Protein–ligand stability analysis
- Understanding molecular flexibility
- Evaluation of interaction stability

Importance

MD simulation provides detailed information about the dynamic behaviour of biological molecules.[10,17]

5.4 Quantitative Structure–Activity Relationship (QSAR)

QSAR is a computational technique that generates a mathematical correlation between chemical structure and biological activity of compounds.[11,12]

Parameters used in QSAR analysis include

- Molecular weight
- Lipophilicity (LogP)
- Electronic properties
- Hydrogen bonding potential.[11,12]

Uses

- Biological activity prediction
- Optimization of leads
- Prediction of potency
- Toxicity evaluation

Significance

QSAR is useful in developing better drug candidates through biological activity prediction.[11,12]

5.5 Pharmacophore Modelling

Pharmacophore modelling identifies the essential structural and chemical features required for a molecule to interact with a biological target and produce therapeutic activity.[13,17]

Important pharmacophore features include

- Hydrogen bond donors
- Hydrogen bond acceptors
- Hydrophobic regions
- Aromatic groups.[13,17]

Applications

- Identification of new drug candidates
- Virtual screening
- Lead optimization

Importance

Pharmacophore modelling helps identify molecules with similar biological activity and improves drug discovery efficiency.[13,17]

5.6 Artificial Intelligence (AI) and Machine Learning (ML)-Based Drug Design

Artificial Intelligence and Machine Learning have become advanced tools in modern CADD by analysing large chemical and biological datasets.[4,14,15]

AI/ML approaches are used to predict

- Drug–target interactions
- Binding affinity
- Toxicity
- ADMET properties
- Novel drug-like molecules [16.20].

RECENT CASE STUDIES SECTION (2023–2026)

Case Study 1: AlphaFold in Drug Discovery

Application: AI predicts protein 3D structures with high accuracy, accelerating structure-based drug design.

Case Study 2: COVID-19 Drug Discovery

Virtual screening and molecular docking rapidly identified potential inhibitors of SARS-CoV-2 proteins.

Case Study 3: AI-designed Antibiotics

Machine learning has been used to discover novel antibiotics effective against multidrug-resistant bacteria



Figure 5: AI-based Drug Discovery Workflow.

Deep learning techniques facilitate

- Molecular synthesis
- Protein structure prediction
- Drug response prediction

Benefits

- Drugs candidate discovery becomes faster
- Greater accuracy in predictions
- Drug design automation techniques.[16,20]

Significance

Incorporation of AI/ML technologies has revolutionized CADD into a data-driven process for effective and innovative drug discovery.[4,14,15]

6. Applications and Case Studies of Computer-Aided Drug Design (CADD)

Computer-Aided Drug Design (CADD) has become an essential approach in modern pharmaceutical research due to its ability to accelerate drug discovery and improve the identification of potential therapeutic molecules. CADD techniques are widely applied in virtual screening, lead identification, drug repurposing, anticancer drug development, antiviral drug discovery, and personalized medicine.[1,3,6]

6.1 Applications of CADD in Drug Discovery

1. Virtual Screening and Lead Identification

Another key application of CADD is virtual screening, which involves using computational techniques to screen large collections of chemicals for possible drug leads.[6,14,19]

It assists in:

- Thorough screening of thousands of chemicals
- Determining molecular interactions
- Identifying promising lead chemicals

Importance

Virtual screening saves time and money in the early stage of drug discovery process.

2. ANTICANCER DRUG DISCOVERY

CADD is significant in the discovery and design of molecules targeting cancer proteins, enzymes, and signaling pathways.[1,3,6]

Some ways in which computation helps are by

- Developing specific inhibitors
- Predicting interactions of drugs with their targets
- Optimizing anticancer drugs

Imatinib Case Study

Target: BCR-ABL tyrosine kinase

CADD Techniques Used

Structure-based drug design and molecular modeling were employed to study how the inhibitor and the target interact.

RESULTS

Imatinib proved to be an effective targeted treatment for chronic myeloid leukemia.

3. ANTIVIRAL DRUG DISCOVERY

CADD approaches are widely used for the development of antiviral agents by targeting essential viral proteins and enzymes.[1,3,6]

Case Study: Saquinavir

Target: HIV protease enzyme

CADD Approach

Structure-based drug design and molecular docking were used to design and optimize protease inhibitors.

Outcome

Saquinavir became an important protease inhibitor used in HIV therapy.[14,19]

4. INFLUENZA DRUG DEVELOPMENT

CADD has contributed to the discovery of antiviral agents by studying viral proteins and designing molecules with improved binding properties.[1,3,6]

Case Study: Zanamivir

Target: Influenza neuraminidase enzyme

CADD Approach

Molecular modelling and structure-based approaches helped understand enzyme inhibition.

Outcome

Zanamivir was developed as an effective neuraminidase inhibitor for influenza treatment.[14,19]

- **STEPS INVOLVED IN COMPUTER – AIDED DRUG DESIGN**

Target Identification
↓
Protein Structure
↓
Virtual Screening
↓
Molecular Docking
↓
Molecular Dynamics
↓
ADMET Prediction
↓
Lead Optimization
↓
Experimental Validation
↓
Clinical Trials

5. DRUG REPURPOSING

CADD helps identify new therapeutic uses of existing drugs by predicting their interactions with different biological targets.[1,3,6]

Advantages

- Reduces development time
- Lowers research cost
- Uses existing safety information.[14,19]

6. ADMET AND TOXICITY PREDICTION

CADD tools predict pharmacokinetic properties and possible toxicity of drug candidates at early stages.[1,3,6]

It helps evaluate

- Absorption
- Distribution
- Metabolism
- Excretion
- Toxicity

Significance

Improves selection of safer drug candidates and reduces failure during later stages.

7. Personalized Medicine

The combination of CADD with genomics and artificial intelligence helps develop personalized treatments according to the molecular profiles of patients.[14,19]

7. Advantages and Limitations of Computer-Aided Drug Design (CADD)

Computer-Aided Drug Design (CADD) has helped revolutionize the current drug discovery process owing to the availability of computationally efficient means for discovering and optimizing drug candidates. There are a number of advantages of CADD over traditional techniques; however, there are some limitations as well.[1,5,6]

7.1 Advantages of CADD

1. Time and Cost Saving

Time and costs of drug discovery are reduced using CADD due to the capability of doing computational analysis and screening before experimentation.

2. Fast Screening of Chemical Libraries

CADD helps in screening of large chemical libraries within a short time in order to identify promising drug candidates.

3. Enhancement of Design and Optimization of Drugs

Through computational methods, structures can be modified in order to improve:

- Drug efficacy,
- Selectivity,
- Stability and
- Pharmacokinetic properties

4. Prediction of Drug-Target Interaction

Methods like molecular docking and molecular dynamic simulation help in the prediction of drug-target interactions including binding affinity.

5. ADMET Predictions at an Early Stage

CADD allows for prediction of Absorption, Distribution, Metabolism, Excretion and Toxicity properties of compounds in order to eliminate unsuitable ones at an early stage.

6. Reduction in Experimental Workload

Potential drug candidates that will undergo laboratory experiments are determined using CADD, hence reducing workload.

7. Rational Drug Discovery Assistance

CADD allows both structure and ligand-based approach for drug designing.[19,13]

7.2 Limitations of CADD

1. Reliance on Data Quality

Reliability of CADD predictions is affected by the quality of structural data, databases, and biological information.[1,5,6]

2. Failure to Capture the Biological Complexity

Biological processes entail complex reactions that may not be fully predicted using computations.

3. Need for Experimental Verification

Predictions made computationally need to be verified using experiments such as in vitro and in vivo testing.[13,19]

4. Protein Flexibility Issues

Protein flexibility is usually not captured by most of the computational techniques, which often work using fixed protein structure.

5. High Computing Demands

Complex techniques such as molecular dynamics simulation and artificial intelligence-based prediction need substantial computing power and knowledge.

6. False Predictions

Some compounds that were identified as potential leads may not prove viable in laboratory tests due to the difference in computational predictions and biological reality.

Table 4: Problems and Potential Solutions In CADD.

Problems	Potential Solution
Poor- data quality	Improved database
Flexibility of proteins	Molecular dynamics modeling
False positives	Experiment
Computational complexity	Cloud computing and GPUs

8. Future Perspectives of Computer-Aided Drug Design (CADD)

Artificial intelligence, machine learning, computational biology, and data analytics will likely shape the future direction of CADD. Advances in computational techniques and biological databases are extending the predictive abilities of CADD for the behaviour of molecules and drug discovery processes.[4,14,15]

Incorporation of artificial intelligence (AI) and machine learning (ML) into CADD technology is revolutionizing the drug discovery process through better prediction of drug-target interactions, binding affinities, toxicities, and pharmacokinetics. AI-based modeling helps to find novel drugs from huge datasets of chemicals and biological information.[16,20]

Future developments in CADD include

1. AI-Driven Molecule Design

The AI and deep learning techniques will allow developing new compounds and improving predictions of their therapeutic effects.

2. New Approaches to Virtual Screening

Future approaches to virtual screening will deliver more reliable predictions due to the integration of molecular modeling, biological data, and machine learning.

3. Omics Technologies Integration

The combination of CADD technology and genomics, proteomics, and metabolomics will make target identification better.

4. Personalized Medicine

By using CADD in combination with patient-specific molecular information, targeted therapies can be developed.

5. Drug Repositioning

Computational methods will be further applied for identifying new therapeutic applications of existing drugs and will save time and money spent on the development.

6. Better Molecular Simulations

Advanced molecular dynamics and simulation technologies will increase precision of predicting interactions between proteins and ligands, molecular stability.

7. Cloud-Based and Automated Drug Discovery Platforms

Future CADD technologies may create cloud-based and automated drug discovery platforms.

Table 5: recent drug discovery using CADD.

DRUG	DISEASE	CADD/AI APPLICATION	CLINICAL SIGNIFICANCE
Sotorasib	Non-small cell lung cancer	Structure-based drug design and molecular modelling	First approved KRAS G12C inhibitor
Adagrasib	Non-small cell lung cancer	Structure-guided lead optimization	Improved targeted therapy
Paxlovid	COVID-19	Structure-based design targeting the viral main protease	Reduced hospitalization in high-risk patients
Asciminib	Chronic myeloid leukemia	Structure-based design of an allosteric inhibitor	Effective in resistant CML
Pirtobrutinib	Mantle cell lymphoma	Computational lead optimization	Active against resistant BTK mutations
Capmatinib	Non-small cell lung cancer	Structure-based optimization	Precision oncology treatment
Tepotinib	Non-small cell lung cancer	Molecular modelling and optimization	Targeted treatment with improved selectivity

9. CONCLUSION

Computer-Aided Drug Design (CADD) has become an essential and innovative approach in modern pharmaceutical research by transforming the traditional drug discovery process into a more rational, efficient, and cost-effective strategy. The integration of computational methods such as virtual screening, molecular docking, molecular dynamics simulation, QSAR analysis, pharmacophore modelling, and artificial intelligence-based approaches has significantly improved the identification and optimization of potential drug candidates.[1,4,14,19]

Virtual screening, as a major component of CADD, enables rapid evaluation of large chemical libraries and helps in selecting promising molecules based on their predicted biological activity, molecular interactions, and drug-like

properties. CADD approaches support various stages of drug discovery, including target identification, lead discovery, lead optimization, and ADMET prediction.[1,4,14,19]

Although challenges such as data limitations, computational requirements, and the need for experimental validation remain, continuous advancements in artificial intelligence, machine learning, and computational biology are improving the accuracy and effectiveness of CADD approaches.[1,4,14,19]

Overall, CADD has emerged as a powerful tool for accelerating drug discovery and development. Its future integration with advanced technologies will further contribute to the discovery of safer, more effective, and personalized therapeutic agents.[1,4,14,19]

The recent achievements in the field of Computer-Aided Drug Discovery have shown that a combination of virtual screening, molecular modeling, artificial intelligence, and biomedical databases can considerably increase the efficiency of the drug discovery process.[24,25] Modern computing platforms allow scientists to screen a large amount of chemicals rapidly, predict interactions between drugs and target molecules, and optimize leads. Future research in the field of high-performance computing, deep learning, and data-driven drug design should result in even more reliable predictions and help to create better and safer therapeutics. Thus, CADD will be crucial for the future generation of pharmaceutical science.[20,22,23]

REFERENCES

1. Sliwoski G, Kothiwale S, Meiler J, Lowe EW. Computational methods in drug discovery. Pharmacological Reviews, 2014; 66(1): 334–395.
2. Anderson AC. The process of structure-based drug design. Chemistry & Biology, 2003; 10(9): 787–797.
3. Hughes JP, Rees S, Kalindjian SB, Philpott KL. Principles of early drug discovery. British Journal of Pharmacology, 2011; 162(6): 1239–1249.
4. Lionta E, Spyrou G, Vassilatis DK, Cournia Z. Structure-based virtual screening for drug discovery: principles, applications and recent advances. Current Topics in Medicinal Chemistry, 2014; 14(16): 1923–1938.
5. Walters, Stahl MT, Murcko MA. Virtual screening—An overview. Drug Discovery Today, 1998; 3(4): 160–178.
6. Meng XY, Zhang HX, Mezei M, Cui M. Molecular docking: A powerful approach for structure-based drug discovery. Current Computer-Aided Drug Design, 2011; 7(2): 146–157.
7. Kitchen DB, Decornez H, Furr JR, Bajorath J. Docking and scoring in virtual screening for drug discovery. Nature Reviews Drug Discovery, 2004; 3: 935–949.
8. Trott O, Olson AJ. AutoDock Vina: Improving the speed and accuracy of docking. Journal of Computational Chemistry, 2010; 31(2): 455–461.
9. Morris GM, Lim-Wilby M. Molecular Docking. Methods in Molecular Biology, 2008; 443: 365–382.
10. Karplus M, McCammon JA. Molecular dynamics simulations of biomolecules. Nature Structural Biology, 2002; 9: 646–652.
11. Cherkasov A, Muratov EN, Fourches D, et al. QSAR modelling: Journal of Medicinal Chemistry, 2014; 57(12): 4977–5010.
12. Hansch C, Leo A. Exploring QSAR: Fundamentals and Applications in Chemistry and Biology. American Chemical Society.

13. Ekins S, Mestres J, Testa B. In silico pharmacology for drug discovery. British Journal of Pharmacology, 2007; 152: 9–20.
14. Vamathevan J, Clark D, Czodrowski P, et al. Applications of machine learning in drug discovery and development. Nature Reviews Drug Discovery, 2019; 18: 463–477.
15. Chen H, Engkvist O, Wang Y, Olivecrona M, Blaschke T. The rise of deep learning in drug discovery. Drug Discovery Today, 2018; 23(6): 1241–1250.
16. Jumper J, Evans R, Pritzel A, et al. Highly accurate protein structure prediction with AlphaFold. Nature, 2021; 596: 583–589.
17. Yu W, MacKerell AD. Computer-aided drug design methods. Methods in Molecular Biology, 2017; 1520: 85–106.
18. Schneider G. Automating drug discovery. Nature Reviews Drug Discovery, 2018; 17: 97–113.
19. Sadybekov AV, Katritch V. Computational approaches streamlining drug discovery. Trends in Pharmacological Sciences, 2023; 44(3): 167–180.
20. Patel H, et al. Artificial intelligence in drug discovery: Advances and future perspectives. Drug Discovery Today, 2022.
21. Sabe VT, Ntombela T, Jhamba LA, et al. Current Trends in Computer-Aided Drug Design and a Highlight of Drugs Discovered via Computational Techniques: A Review. European Journal of Medicinal Chemistry, 2021.
22. Santana K, et al. Applications of Virtual Screening in Bioprospecting: Facts, Shifts, and Perspectives to Explore the Chemo-Structural Diversity of Natural Products. Frontiers in Chemistry, 2021.
23. Gorgulla C. Recent Developments in Structure-Based Virtual Screening Approaches, 2022.
24. Deng J, Yang Z, Ojima I, et al. Artificial Intelligence in Drug Discovery: Applications and Techniques, 2021.
25. Murugan NA, Podobas A, Gadioli D, et al. A Review on Parallel Virtual Screening Softwares for High Performance Computers, 2021.
26. Bonner S, Barrett IP, Ye C, et al. A Review of Biomedical Datasets Relating to Drug Discovery: A Knowledge Graph Perspective, 2021.
27. Ouma RB, Ngari SM, Kibet JK. *A Review of the Current Trends in Computational Approaches in Drug Design and Metabolism. Discover Public Health, 2024.
28. Talevi A. *Computer-Aided Drug Discovery and Design: Recent Advances and Future Prospects. Methods in Molecular Biology, 2024.
29. Deep Machine Learning for Computer-Aided Drug Design. Frontiers in Drug Discovery, 2022.
30. A Comprehensive Survey of Prospective Structure-Based Virtual Screening for Early Drug Discovery in the Past Fifteen Years. International Journal of Molecular Sciences, 2022.
31. Emerging Frontiers in Virtual Drug Discovery: From Quantum Mechanical Methods to Deep Learning Approaches. Current Opinion in Chemical Biology, 2022.
32. Computer Especially AI-Assisted Drug Virtual Screening and Design in Traditional Chinese Medicine. Phytomedicine, 2022.
33. A Review of Approaches in Computer-Aided Drug Design in Drug Discovery. GSC Biological and Pharmaceutical Sciences, 2022.
34. Review of Modern Computer-Aided Drug Design Methods. International Journal of Biology and Life Sciences, 2022.

35. Artificial Intelligence in Virtual Screening: Transforming Drug Research and Discovery—A Review. Journal of Bio-X Research, 2025.
36. Computer Aided Drug Design for Multi-Target Drug Design: SAR/QSAR, Molecular Docking and Pharmacophore Methods — 2017.
37. Recent Developments in Structure-Based Virtual Screening Approaches — 2023 (published as a review in Annual Review of Biomedical Data Science; an earlier preprint appeared in 2022).
38. Docking-Based Generative Approaches in the Search for New Drug Candidates — 2023.
39. ToDD: Topological Compound Fingerprinting in Computer-Aided Drug Discovery — 2022 (NeurIPS conference paper).
40. Virtual Screening in Drug Discovery: Recent Advances and Applications — 2021.
41. Advances in Molecular Docking for Structure-Based Drug Design — 2022.
42. Artificial Intelligence and Deep Learning in Modern Drug Discovery — 2019.
43. Pharmacophore Modelling in Drug Discovery: Principles and Applications — 2018.
44. Recent Advances in QSAR Modelling for Drug Discovery — 2020.
45. Molecular Dynamics Simulation in Structure-Based Drug Design — 2021.
46. Computational Approaches for Drug Repurposing Using Artificial Intelligence — 2022.
47. Recent Progress in Computer-Aided Drug Design and Virtual Screening — 2023.